COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. (Q53288733)

13 May 2018

title

COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. (English)

1 reference

13 May 2018

esophageal squamous cell carcinoma

main subject

chemoradiotherapy

0 references

1 reference

Yasunori Akutsu

1

1 reference

13 May 2018

Naoyuki Hanari

2

1 reference

13 May 2018

Gulbostan Yusup

3

1 reference

13 May 2018

Aki Komatsu-Akimoto

4

1 reference

13 May 2018

Norimasa Ikeda

5

1 reference

13 May 2018

Mikito Mori

6

1 reference

13 May 2018

Yasuo Yoneyama

7

1 reference

13 May 2018

Satoshi Endo

8

1 reference

13 May 2018

Yukimasa Miyazawa

9

1 reference

13 May 2018

Hisahiro Matsubara

10

1 reference

13 May 2018

publication date

25 March 2011

1 reference

13 May 2018

Annals of Surgical Oncology

published in

1 reference

13 May 2018

volume

18

1 reference

13 May 2018

issue

10

1 reference

13 May 2018

page(s)

2946-2951

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1245/s10434-011-1645-z

exact match

0 references

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Cyclooxygenase-2: a novel target for cancer chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Epidemiology of non-steroidal anti-inflammatory drugs and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1645-Z

10.1245/S10434-011-1645-Z

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

Dimensions Publication ID

0 references

1 reference

13 May 2018